^
Association details:
| Biomarker: | PLK1 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy + PLK1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
473P - PLK1 expression and KRAS mutations in colorectal cancer
Published date:
09/14/2020
Excerpt:
Among PLK1 expression groups, proportionate increases in dMMR/MSI-H, TMB, immune cell populations, and immune checkpoint gene expression suggest a potential response to immunotherapy in tumors with increased PLK1 expression. Combining immunotherapy with a PLK1 inhibitor might be a synergistic approach to increase sensitivity in PLK1-overexpressing CRC regardless of KRAS status.
